Masato Habuka: Division of Nephrology, Niigata Prefectural Shibata Hospital, 1-2-8 Honcho, Shibata City, Niigata, 957-8588, Japan. lucky_palace1010@yahoo.co.jp. ORCID
Chihiro Sakurazawa: Division of Nephrology, Niigata Prefectural Shibata Hospital, 1-2-8 Honcho, Shibata City, Niigata, 957-8588, Japan.
Yuichi Sakamaki: Division of Nephrology, Niigata Prefectural Shibata Hospital, 1-2-8 Honcho, Shibata City, Niigata, 957-8588, Japan.
Asa Ogawa: Division of Nephrology, Niigata Prefectural Shibata Hospital, 1-2-8 Honcho, Shibata City, Niigata, 957-8588, Japan.
Suguru Yamamoto: Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ichiei Narita: Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Amyloidosis is characterized by the deposition of insoluble amyloid fibrils formed by disease-specific precursor proteins in the extracellular interstitium of various organs throughout the body, resulting in organ damage. Patients with amyloidosis often develop end-stage kidney disease (ESKD), which can be managed with dialysis or kidney transplantation. Peritoneal dialysis (PD) is advantageous over hemodialysis (HD) in managing the circulatory dynamics and removing the precursor proteins of amyloid fibrils. However, the clinical course of PD using an amyloid-deposited peritoneum has not been reported. In this paper, we describe a rare case of systemic AA amyloidosis with amyloid deposition in the peritoneum at the beginning of PD. The peritoneal equilibrium test (PET) at PD initiation revealed a high transport rate. The dialysis solution was temporarily changed to a high-glucose concentration peritoneal dialysate, and a weekly extracorporeal ultrafiltration method was added. The patient continued with PD treatment without any complications. The PET category changed from "high" to "high average" during the subsequent PD treatment course. The serum amyloid A levels improved post-nephrectomy and remained in the normal range. Amyloid A was not detected in the dialysate drainage. In conclusion, the amyloid-deposited peritoneum has no uniform effect on the clinical course of PD. Moreover, amyloidosis therapy can alter the peritoneal function with amyloid deposition. However, future studies should investigate the exact mechanism of the alteration of peritoneal function with amyloidosis therapy.
Browning MJ, Banks RA, Harrison P, Tribe CR, Fraley CT, Zachary G, et al. Continuous ambulatory peritoneal dialysis in systemic amyloidosis and end-stage renal disease. J R Soc Med. 1984;77:189���92. https://doi.org/10.1177/014107688407700306 .
[DOI: 10.1177/014107688407700306]
Habuka M, Nishikiori M, Oikawa C, Takahashi M, Sakamaki Y, Ogawa A, et al. Systemic amyloid A amyloidosis Secondary to xanthogranulomatous pyelonephritis. Intern Med. 2024;63:593���9. https://doi.org/10.2169/internalmedicine.1806-23 .
[DOI: 10.2169/internalmedicine.1806-23]
Boll��e G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol. 2008;3:375���81. https://doi.org/10.2215/cjn.02470607 .
[DOI: 10.2215/cjn.02470607]
Gertz MA, Kyle RA, O���Fallon WM. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med. 1992;152:2245���50.
[DOI: 10.1001/archinte.1992.00400230061010]
Cantaluppi A. CAPD and systemic diseases. Clin Nephrol. 1988;30:S8-12.
[PMID: 3052963]
Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29:674���81. https://doi.org/10.1200/jco.2010.30.5235 .
[DOI: 10.1200/jco.2010.30.5235]
Anand SK, Sanchorawala V, Verma A. Systemic amyloidosis and kidney transplantation: an update. Semin Nephrol. 2024;44: 151496. https://doi.org/10.1016/j.semnephrol.2024.151496 .
[DOI: 10.1016/j.semnephrol.2024.151496]
Nakayama S, Kinugasa S, Hirose T, Miyake Y, Ota K, Onzo-Toyama M, et al. A case of light chain (AL) amyloidosis with heart failure, renal dysfunction, and heparin-induced thrombocytopenia successfully treated with peritoneal dialysis. CEN Case Rep. 2021;10:214���9. https://doi.org/10.1007/s13730-020-00539-w .
[DOI: 10.1007/s13730-020-00539-w]
Stofer F, Barretto MF, Gouvea AL, Ribeiro M, Neves M, Gismondi RA, et al. A rare case of ascites due to peritoneal amyloidosis. Am J Case Rep. 2016;17:439���43. https://doi.org/10.12659/ajcr.898357 .
[DOI: 10.12659/ajcr.898357]
Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003;124:969���77. https://doi.org/10.1378/chest.124.3.969 .
[DOI: 10.1378/chest.124.3.969]
Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346���52. https://doi.org/10.1182/blood-2011-01-330738 .
[DOI: 10.1182/blood-2011-01-330738]
Tanaka T, Naito T, Midori Y, Nosaka T, Takahashi K, Ofuji K, et al. Gastrointestinal AA amyloidosis secondary to chronic pyelonephritis presenting with refractory diarrhea and severe hypoalbuminemia. Clin J Gastroenterol. 2021;14:1642���8. https://doi.org/10.1007/s12328-021-01508-1 .
[DOI: 10.1007/s12328-021-01508-1]
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361���71. https://doi.org/10.1056/NEJMoa070265 .
[DOI: 10.1056/NEJMoa070265]
Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997;51:182���6. https://doi.org/10.1038/ki.1997.22 .
[DOI: 10.1038/ki.1997.22]
Rashid G, Korzets Z, Bernheim J. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis. Isr Med Assoc J. 2006;8:36���9.
[PMID: 16450750]
